Related Experiment Video
Updated: Jun 24, 2026

09:32
Protocols for Testing the Toxicity of Novel Insecticidal Chemistries to Mosquitoes
Published on: February 13, 2019
16.2K
Linalool as a potential agent against Toxoplasma gondii: an in vitro study
Kimia Goudarzi1,2, Keivan Sahebi1,3, Ehsan Zandi4
1School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
BMC Research Notes
|November 19, 2025
Summary
Linalool demonstrates dose-dependent activity against Toxoplasma gondii tachyzoites in vitro. This study suggests linalool as a potential therapeutic agent for toxoplasmosis, warranting further investigation.
Area of Science:
- Parasitology
- Pharmacology
- Natural Products Chemistry
Background:
- Toxoplasmosis, a widespread zoonotic disease caused by *Toxoplasma gondii*, necessitates new treatments due to limitations of current therapies.
- Existing treatments for toxoplasmosis exhibit limited efficacy and potential side effects, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To investigate the in vitro antiparasitic effects of linalool against *Toxoplasma gondii* tachyzoites.
- To determine the dose-dependent activity of linalool and compare its efficacy to a positive control (saponin).
Main Methods:
- *Toxoplasma gondii* RH strain tachyzoites were exposed to various concentrations of linalool.
- Flow cytometry was employed to analyze parasite mortality rates.
- Results were compared against a saponin positive control and a no-treatment negative control.
Main Results:
- Linalool exhibited dose-dependent *in vitro* activity against *Toxoplasma gondii* tachyzoites.
- Mortality rates increased with linalool concentration, reaching 74.44% at 1200 µg/mL, surpassing the positive control (67.87%).
- These findings indicate linalool's extracellular antiparasitic potential against *T. gondii*.
Conclusions:
- Linalool shows promising *in vitro* efficacy against *Toxoplasma gondii* tachyzoites.
- The study provides a foundation for further research into linalool's intracellular and *in vivo* activity and safety for treating toxoplasmosis.
More Related Videos
Related Concept Videos
Toxoplasmosis
Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

